AFLIBERCEPT (Eylea®)
Clinical Indication
Wet age related macular degeneration. Diabetic macular oedema. Macular oedema due to central retinal vein occlusion and branch retinal vein occlusion. Choroidal neovascularisation.
Comments
In line with NICE TA294, NICE TA346, NICE TA305, NICE TA409, NICE TA486
Date of classification
October 2015
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.